নির্দেশনা
Treatment : Ertapenem is indicated for the treatment of patients with moderate to severe infections caused by susceptible strains of microorganisms, as well as initial empiric therapy prior to the identification of causative organisms in the infections listed below: Complicated Intra-Abdominal Infections ... Read more Treatment : Ertapenem is indicated for the treatment of patients with moderate to severe infections caused by susceptible strains of microorganisms, as well as initial empiric therapy prior to the identification of causative organisms in the infections listed below: Complicated Intra-Abdominal Infections Complicated Skin and Skin Structure Infections including diabetic lower extremity and diabetic foot infections Community Acquired Pneumonia Complicated Urinary Tract Infections including pyelonephritis Acute Pelvic Infections including postpartum endomyometritis, septic abortion and post surgical gynecologic infections Bacterial Septicaemia Prevention : Ertapenem is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery.
Composition
ফার্মাকোলজি
Ertapenem for Injection is a sterile, synthetic, long-acting, parenteral, 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics, such as penicillins and cephalosporins, with activity against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria. Ertapenem exhibits a bactericidal mode of action. It works by binding to and inhibiting bacterial penicillin-binding proteins (PBPs). In Escherichia coli, it has a strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preferential binding to PBPs 2 and 3. Upon binding to PBPs, ertapenem inhibits bacterial cell wall synthesis by interfering with the lengthening and strengthening of the peptidoglycan portion of the cell wall, thereby inhibiting cell wall synthesis.
মাত্রা ও সেবনবিধি
Adults (>12 years) : 1 gm given once a day. Pediatric (3 months to 12 years) : 15 mg/kg twice daily (not to exceed 1 g/day). Ertapenem may be administered by IV infusion or IM injection. When administered intravenously, it should be infused over a period of 30 minutes. IM administration of Ertapenem may be used as an alternative to IV administration in the treatment of those infections for which intramuscular therapy is appropriate. The usual duration of therapy with Ertapenem is 3 to 14 days but varies by the type of infection and causative pathogen(s). When clinically indicated, a switch to an appropriate oral antimicrobial maybe implemented if clinical improvement has been observed. Prophylaxis of surgical site infection following elective colorectal surgery : To prevent surgical site infections following surgery in adults, the recommended dosage is 1 g IV administered as a single intravenous dose given 1 hour prior to the surgical incision. Patients with renal insufficiency : Ertapenem may be used for the treatment of infections in adult patients with renal insufficiency. In patients whose creatinine clearance is >30 mL/min no dosage adjustment is necessary. Adult patients with advanced renal insufficiency (creatinine clearance ≤30 mL/min), including those on haemodialysis, should receive 500 mg daily. There are no data in paediatric patients with renal insufficiency. Patients on Haemodialysis : If Ertapenem is given at least 6 hours prior to haemodialysis, no supplementary dose is needed. When adult patients on haemodialysis are given Ertapenem within 6 hours prior to haemodialysis, a supplementary 30% dose is recommended following the haemodialysis session. There are no data in patients undergoing peritoneal dialysis or haemofiltration. There are no data in paediatric patients on haemodialysis. No dosage adjustment is recommended in patients with impaired hepatic function
প্রতিনির্দেশনা
Ertapenem is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams. Due to the use of lidocaine HCl as a diluent, intramuscular administration of Ertapenem is contraindicated in patients with a known hypersensitivity to local anaesthetics of the amide type and in patients with severe shock or heart block.
পার্শ্ব প্রতিক্রিয়া
Most adverse experiences reported in these clinical studies were described as mild to moderate in severity. The most common drug-related adverse experiences reported during parenteral therapy with Ertapenem include Headache, Infused vein complication, phlebitis/ thrombophlebitis, Diarrhoea, nausea and vomiting. Other uncommon side effects include- Dizziness, somnolence, insomnia, seizure, confusion, Extravasation, hypotension, Dyspnoea, Oral candidiasis, constipation, acid regurgitation, C. difficile-associated diarrhoea, dry mouth, dyspepsia, anorexia, Erythema, pruritus, Abdominal pain, taste perversion, asthenia/fatigue, candidiasis, oedema/swelling, fever, pain, chest pain, Vaginal pruritus.
গর্ভাবস্থায় ও স্তন্যদানকালে
Ertapenem has been assigned to pregnancy category B by the FDA. There are no adequate and well-controlled studies in pregnant women. Ertapenem should be used during pregnancy only if the potential benefit justifies the potential risk to the mother and foetus. Ertapenem is excreted in human milk. Caution should be exercised when Ertapenem is administered to a nursing woman.
সতর্কতা
Before initiating therapy with Ertapenem, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, other beta-lactams and other allergens. If an allergic reaction to Ertapenem occurs, discontinue the drug immediately. Serious anaphylactic reactions require immediate emergency treatment. As with other antibiotics, prolonged use of Ertapenem may result in overgrowth of non-susceptible organisms. Repeated evaluation of the patient's condition is essential. If superinfection occurs during therapy, appropriate measures should be taken. Pseudomembranous colitis has been reported with nearly all antibacterial agents, including Ertapenem, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea subsequent to the administration of antibacterial agents. Studies indicate that a toxin produced by Clostridium difficile is a primary cause of "antibiotic-associated colitis".
থেরাপিউটিক ক্লাস
Other beta-lactam Antibiotics